• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-1/A filed by Onconetix Inc.

    11/12/24 10:53:57 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ONCO alert in real time by email
    S-1/A 1 ea0220717-s1a1_onconetix.htm AMENDMENT NO. 1 TO FORM S-1

    As filed with the Securities and Exchange Commission on November 12, 2024

    Registration No. 333-282959

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    Amendment No. 1 to

    FORM S-1

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Onconetix, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   2834   83-2262816
    (State or other jurisdiction of
    incorporation or organization)
      (Primary Standard Industrial
    Classification Code Number)
      (I.R.S. Employer
    Identification No.)

     

    201 E. Fifth Street, Suite 1900
    Cincinnati, Ohio 45202
    Telephone: (513) 620-4101
    (Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

     

    Karina M. Fedasz
    Interim Chief Financial Officer
    201 E. Fifth Street, Suite 1900
    Cincinnati, Ohio 45202
    Telephone: (513) 620-4101
    (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

     

    with copies to:

    Barry I. Grossman, Esq.
    Jessica Yuan, Esq.
    Ellenoff Grossman & Schole LLP
    1345 Avenue of the Americas
    New York, NY 10105
    Phone: (212) 370-1300
    Fax: (212) 370-7889

     

    Approximate date of commencement of proposed sale to the public: From time to time after this registration statement becomes effective.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission acting pursuant to said Section 8(a), may determine.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    Onconetix, Inc. is filing this Amendment No. 1 (this “Amendment”) to its Registration Statement on Form S-1 (File No. 333-282959) (the “Registration Statement”) as an exhibit-only filing to file Exhibit 5.1. Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16(a) of Part II of the Registration Statement, the signature page to the Registration Statement and the filed exhibit. The remainder of the Registration Statement is unchanged and has been omitted.

     

     

     

     

    PART II
    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits and Financial Statement Schedules.

     

            Incorporated by Reference
    Exhibit No.   Description   Form   Exhibit   Filing Date
    2.1*   Share Exchange Agreement, dated December 15, 2023, by and among the Company, Proteomedix, Thomas Meier and the Sellers.   8-K   2.1   December 21, 2023
    3.1*   Amended and Restated Certificate of Incorporation filed with Delaware Secretary of State on February 23, 2022.   8-K   3.1   February 24. 2022
    3.2*   Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation   8-K   3.1   April 24, 2023
    3.3*   Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation.   8-K   3.1   December 21, 2023
    3.4*   Fourth Amended and Restated Bylaws of the Company.   8-K   3.2   December 21, 2023
    3.5*   Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated September 24, 2024.   8-K   3.1   September 20, 2024
    3.6*   Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended, of Onconetix, Inc., dated September 24, 2024.   8-K   3.1   September 24, 2024
    4.1*   Specimen Common Stock Certificate.   S-1   4.1   October 8, 2021
    4.2*   Description of Registered Securities.   10-K   4.2   April 11, 2024
    4.3*   Certificate of Designation of Series A Preferred Stock.   8-K   3.1   October 3, 2023
    4.4*   Certificate of Designation of Series B Convertible Preferred Stock.   8-K   4.1   December 21, 2023
    4.5*   Form of Inducement PIO.   8-K   4.1   August 3, 2023
    4.6*   Form of Inducement PIO.     8-K   4.1   July 11, 2024
    4.7*   Form of Altos Warrants.   8-K   4.1   September 24, 2024
    4.8*   Form of Warrant.   8-K   4.1   October 3, 2024
    4.9*   Certification of Designation of Series C Preferred Stock.   8-K   3.1   October 3, 2024
    5.1**   Opinion of Ellenoff Grossman & Schole LLP as to the legality of the securities being registered.            
    10.1*   2019 Equity Incentive Plan.   S-1   10.1   October 8, 2021
    10.2*   2022 Equity Incentive Plan.   S-1/A   10.2   November 29, 2021
    10.3*   2019 Equity Incentive Plan Form of Stock Option Grant Agreement.   S-1   10.3   October 8, 2021
    10.4*   2022 Equity Incentive Plan Form of Incentive Stock Option Agreement (Employee).   S-1/A   10.4   January 6, 2022
    10.5*   2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Consultant).   S-1/A   10.5   January 6, 2022
    10.6*   2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Non-Employee Director).   S-1/A   10.6   January 6, 2022
    10.7*   2022 Equity Incentive Plan Form of Nonstatutory Stock Option Agreement (Employee).   S-1/A   10.7   January 6, 2022
    10.8*   Lease Agreement, dated as of April 29, 2021, between the Registrant and Regus Management Group, LLC.   S-1   10.11   October 8, 2021
    10.9*   Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of July 19, 2019.   S-1   10.12   October 8, 2021

     

    II-1

     

     

    10.10*   Project Addendum 1 to Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of October 9, 2019.   S-1   10.13   October 8, 2021
    10.11*   Letter Agreement between the Registrant and Ology Bioservices, Inc., dated as of January 9, 2020.   S-1   10.14   October 8, 2021
    10.12*   Project Addendum II to Master Services Agreement between the Registrant and Ology Bioservices, Inc., effective as of May 21, 2021   S-1   10.15   October 8, 2021
    10.13*   Form of Employment Agreement with Joseph Hernandez   S-1   10.16   October 8, 2021
    10.14*   Form of Employment Agreement with Erin Henderson   S-1   10.17   October 8, 2021
    10.15*   Form of Employment Agreement with Jon Garfield.   S-1   10.18   October 8, 2021
    10.16*   Form of Employment Agreement with Neil Campbell.   8-K   10.1   October 10, 2023
    10.17*   Form of Employment Agreement with Bruce Harmon.   8-K   10.2   October 10, 2023
    10.18*   Form of Employment Agreement with Ralph Schiess.   10-K   10.21   April 11, 2024
    10.19*   Amendment to Employment Agreement, dated October 15, 2020, by and between Proteomedix and Ralph Schiess.   10-K   10.22   April 11, 2024
    10.20*   Amendment to Employment Agreement by and between Proteomedix and Ralph Schiess.   10-K   10.23   April 11, 2024
    10.21*   Form of Employment Agreement with Christian Brühlmann.   10-K   10.24   April 11, 2024
    10.22*   Amendment to Employment Agreement, dated October 16, 2020, by and between Proteomedix and Christian Brühlmann.   10-K   10.25   April 11, 2024
    10.23*   Amendment to Employment Agreement by and between Proteomedix and Christian Brühlmann.   10-K   10.26   April 11, 2024
    10.24*   General Release of Claims, dated October 5, 2023, by and between Jon Garfield and the Company.   8-K   99.1   October 10, 2023
    10.25*   Release, dated January 10, 2024, by and between the Company and Dr. Neil Campbell.   8-K   99.1   January 12, 2024
    10.26*   Form of Indemnification Agreement for Directors and Officers.   8-K   10.3   October 10, 2023
    10.27*   Form of Securities Purchase Agreement, dated as of April 13, 2022, by and among the Company and the Purchasers.   8-K   10.1   April 19, 2022
    10.28*   Form of Registration Rights Agreement, dated as of April 13, 2022, by and among the Company and the Purchasers.   8-K   10.2   April 19, 2022
    10.29*   Form of Securities Purchase Agreement, dated as of August 9, 2022, by and among the Company and the Purchasers.   8-K   10.1   August 11, 2022
    10.30*   Form of Registration Rights Agreement, dated as of August 9, 2022, by and among the Company and the Purchasers.   8-K   10.2   August 11, 2022
    10.31*   Settlement Agreement and Release, dated October 9, 2022, by and between the Registrant and Boustead Securities, LLC.   10-Q   10.3   November 14, 2022
    10.32*   Amendment No. 1 to Project Addendum 2 to Master Services Agreement, dated as of April 20, 2022, by and between the Registrant and Ology Bioservices, Inc.   10-Q   10.1   May 13, 2022

     

    II-2

     

     

    10.33*   Amendment #1 to Exclusive License Agreement, dated as of May 11, 2022, by and between the Registrant and St. Jude Children’s Research Hospital, Inc.   10-Q   10.2   May 13, 2022
    10.34*   Patent & Technology License Agreement, dated November 18, 2022, between the Company and the University of Texas Health Science Center at San Antonio.   10-Q   10.1   May 12, 2023
    10.35*   Co-Development Agreement, dated February 1, 2023, between the Company and AbVacc, Inc.   10-Q   10.2   May 12, 2023
    10.36*   At-the-Market Offering Agreement, dated March 29, 2023, between the Company and H.C. Wainwright & Co., LLC.   8-K   1.1   March 29, 2023
    10.37*   Asset Purchase Agreement, dated April 19, 2023, between the Company and Veru Inc.   8-K   10.1   April 20, 2023
    10.38*   Amendment to Asset Purchase Agreement, dated September 29, 2023, between the Company and Veru Inc.   8-K   10.1   October 3, 2023
    10.39*   Form of Non-Competition and Non-Solicitation Agreement, dated April 19, 2023.   8-K   10.1   April 20, 2023
    10.40*   Asset Purchase Agreement, dated June 13, 2023, by and among WraSer, Xspire, and the Company.   8-K   10.1   June 14, 2023
    10.41*   Management Services Agreement, dated June 13, 2023, by and among WraSer, Xspire and the Company.   8-K   10.2   June 14, 2023
    10.42*   Form of Amendment, dated October 5, 2023, to Asset Purchase Agreement, dated June 13, 2023, by and among WraSer, Xspire, Legacy-Xspire Holdings, LLC, and the Company.   10-Q   10.14   October 20, 2023
    10.43*   Exclusive Distribution Agreement, dated September 20, 2023, between the Company and Cardinal Health 105, LLC.   10-Q   10.6   November 17, 2023
    10.44*   Form of Lock-Up Agreement, dated December 15, 2023, by and among the Company and certain stockholders of Proteomedix.   8-K   10.1   December 21, 2023
    10.45*   Form of Non-Competition and Non-Solicitation Agreement, dated December 15, 2023, by and among the Company and certain stockholders of Proteomedix.   8-K   10.2   December 21, 2023
    10.46*   Form of Stockholder Support Agreement, dated December 15, 2023, by and among the Company, Proteomedix, and certain stockholders of Proteomedix   8-K   10.3   December 21, 2023
    10.47*   Form of Subscription Agreement, dated December 15, 2023, by and among the Company, Proteomedix, and the PMX Investor.   8-K   10.4   December 21, 2023
    10.48*   Separation Agreement, dated January 17, 2024, between the Company and Erin Henderson.   8-K   10.1   January 19, 2024
    10.49*   Consulting Agreement, dated January 17, 2024, between the Company and The Aetos Group.   8-K   10.2   January 19, 2024
    10.50*   Debenture, dated January 23, 2024 issued to the PMX Investor   8-K   10.1   January 29, 2024
    10.51*   Consulting Agreement, dated January 4, 2024, by and between the Company and Thomas Meier.   8-K   10.1   February 12, 2024

     

    II-3

     

     

    10.52*   License Agreement, dated March 27, 2023, between Proteomedix and Laboratory Corporation of America Holdings.   10-K   10.55   April 11, 2024
    10.53*   Form of Inducement Letter   8-K   10.1   August 1, 2023
    10.54*   Form of Letter Agreement.   8-K   10.1   August 3, 2023
    10.55*   Amendment to Debenture, dated April 24, 2024, issued to the PMX Investor.   8-K   10.2   April 26, 2024
    10.56*   Forbearance Agreement, dated April 24, 2024, by and between the Company and Veru Inc.   8-K   10.1   April 26, 2024
    10.57*   Master Research Services Agreement, dated October 1, 2022, by and between Proteomedix AG and Immunovia, AB   S-1/A   10.60   June 25, 2024
    10.58*   Collaboration Agreement, dated July 19, 2021, by and between Proteomedix AG and New Horizon Health Limited   S-1/A   10.61   June 25, 2024
    10.59*   Amendment No. 1, dated June 26, 2023, to Collaboration Agreement, dated July 19, 2021, by and between Proteomedix AG and New Horizon Health Limited   S-1/A   10.62   June 25, 2024
    10.60*   Release Agreement, dated June 10, 2024, between the Company and Bruce Harmon.   8-K   99.1   June 13, 2024
    10.61*   Consulting Agreement, dated June 10, 2024, between the Company and Karina Fedasz.   8-K/A   10.1   June 14, 2024
    10.62*   Form of Inducement Letter   8-K   10.1   July 11, 2024
    10.63*   Amended and Restated Forbearance Agreement between the Company and Veru, dated September 19, 2024   8-K   10.1   September 20, 2024
    10.64*   Form of Securities Purchase Agreement dated October 2, 2024 relating to the sale of the Series C Preferred Stock and Warrants   8-K   10.1   October 3, 2024
    10.65*   Form of Registration Rights Agreement dated as of October 2, 2024 relating to the resale of the shares of Common Stock underlying the Series C Preferred Stock and Warrants   8-K   10.2   October 3, 2024
    10.66*   Form of ELOC Purchase Agreement dated October 2, 2024   8-K   10.3   October 3, 2024
    10.67*   Form of ELOC Registration Rights Agreement dated October 2, 2024   8-K   10.4   October 3, 2024
    16*   Letter from EisnerAmper LLP, dated October 21, 2024.   8-K   6.1   October 21, 2024
    21*   List of Subsidiaries.   10-K   21   April 11, 2024
    23.1*   Consent of CBIZ CPAs P.C.   S-1   23.1   November 1, 2024
    23.2*   Consent of EisnerAmper LLP.   S-1   23.2   November 1, 2024
    23.3*   Consent of BDO AG.   S-1   23.3   November 1, 2024
    23.4**   Consent of Ellenoff Grossman & Schole (included as part of Exhibit 5.1 hereto).            
    24*   Power of Attorney   S-1       November 1, 2024
    107   Filing Fee Table.            
    101.INS*   XBRL Instance Document.       101.INS*    
    101.SCH*   XBRL Taxonomy Schema Linkbase Document.       101.SCH*    
    101.CAL*   XBRL Taxonomy Calculation Linkbase Document.       101.CAL*    
    101.DEF*   XBRL Taxonomy Definition Linkbase Document.       101.DEF*    
    101.LAB*   XBRL Taxonomy Labels Linkbase Document.       101.LAB*    
    101.PRE*   XBRL Taxonomy Presentation Linkbase Document.       101.PRE*    
    104*   Cover Page Interactive Data File (Embedded as Inline XBRL document and contained in Exhibit 101).       104*    

     

    *Previously filed

     

    **Filed herewith

     

    †Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

     

    #Certain portions of this exhibit (indicated by “[*]” have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K as we have determined they (1) are not material and (2) are the type that the Company treats as private or confidential. The Registrant hereby agrees to furnish a copy of any omitted portion to the SEC upon request.

     

    II-4

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cincinnati, Ohio, on November 12, 2024.

     

      ONCONETIX, INC.
       
      By: /s/ Karina M. Fedasz
      Name:  Karina M. Fedasz
      Title: Interim Chief Financial Officer

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    *   Interim Chief Executive Officer   November 12, 2024
    Ralph Schiess   (Principal Executive Officer)    
             
    /s/ Karina M. Fedasz   Interim Chief Financial Officer   November 12, 2024
    Karina M. Fedasz   (Principal Financial and Accounting Officer)    
             
    *   Chairman of the Board and Director   November 12, 2024
    James Sapirstein        
             
    *   Director   November 12, 2024
    Thomas Meier        
             
    *   Director   November 12, 2024
    Timothy Ramdeen        
             
    *   Director   November 12, 2024
    Ajit Singh        
             
    *   Director   November 12, 2024
    Simon Tarsh        

     

    Pursuant to Power of Attorney

     

    By: /s/ Karina M. Fedasz  
      Karina M. Fedasz  
      Attorney-in-Fact  

     

     

    II-5

     
    Get the next $ONCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ONCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONCO
    SEC Filings

    View All

    SEC Form DEF 14A filed by Onconetix Inc.

    DEF 14A - Onconetix, Inc. (0001782107) (Filer)

    1/2/26 9:32:07 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Onconetix Inc.

    EFFECT - Onconetix, Inc. (0001782107) (Filer)

    12/29/25 12:15:21 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Onconetix Inc.

    424B3 - Onconetix, Inc. (0001782107) (Filer)

    12/23/25 4:05:39 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Romano Sarah

    3 - Onconetix, Inc. (0001782107) (Issuer)

    12/12/25 6:04:58 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Tarsh Simon acquired 39 shares and was granted 618 shares, increasing direct ownership by 65,700% to 658 units (SEC Form 4)

    4 - Onconetix, Inc. (0001782107) (Issuer)

    8/19/25 4:05:27 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Meier Thomas acquired 39 shares and was granted 618 shares (SEC Form 4)

    4 - Onconetix, Inc. (0001782107) (Issuer)

    8/19/25 4:05:25 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novel Cancer Platforms Converge as Clinical Data Reshapes Treatment Paradigms

    Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 7, 2025 /PRNewswire/ -- Equity Insider News Commentary – Major pharmaceutical companies presenting at the European Society for Medical Oncology Congress October 17-21[1] are unveiling pivotal survival data[2] and late-breaking lung cancer[3] results that demonstrate how diverse mechanisms are succeeding where traditional approaches stalled, while regulatory agencies issued multiple September approvals spanning gene therapies, bispecifics, and novel delivery systems[4]. The momentum reflects a fundamental shift as researchers discovered how cancer hijacks immune pathways to evade attack, spurring develop

    10/7/25 8:00:00 AM ET
    $ENGN
    $GTBP
    $IMAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc.

    CINCINNATI, OH, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) ("Onconetix" or the "Company") a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men's health and oncology, announced the September 22, 2025 signing and closing of a private placement of (i) shares of the Company's Series D Convertible Preferred Stock, $0.00001 par value (the "Series D Preferred Stock"), and (ii) warrants (the "Warrants") to purchase up to an aggregate of 4,362,827 shares of the Company's common stock, $0.00001 par value per share (the "Common Stock"), for an aggregate purchase price of approximately $12.9 million

    9/26/25 8:30:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement

    CINCINNATI, OH & FORT LEE, NJ, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO), a commercial-stage biotechnology company focused on innovative solutions for men's health and oncology, and Ocuvex Therapeutics, Inc., a leader in ophthalmic innovation, today announced the mutual termination of their previously announced definitive merger agreement, dated July 16, 2025. After careful consideration and constructive dialogue, both companies have jointly determined that pursuing independent paths is in the best interests of their respective stakeholders. This decision reflects the strong commitment of both Onconetix and Ocuvex to advancing their respective missions and deliver

    9/26/25 8:15:00 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Leadership Updates

    Live Leadership Updates

    View All

    Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

    Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

    10/8/24 5:00:00 AM ET
    $ENTO
    $OCS
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ONCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Onconetix Inc.

    SC 13G - Onconetix, Inc. (0001782107) (Subject)

    11/14/24 11:19:35 AM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Onconetix Inc.

    SC 13D - Onconetix, Inc. (0001782107) (Subject)

    10/1/24 4:35:03 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Onconetix Inc.

    SC 13D - Onconetix, Inc. (0001782107) (Subject)

    10/1/24 4:35:03 PM ET
    $ONCO
    Biotechnology: Pharmaceutical Preparations
    Health Care